FARXIGA Significantly Reduced the Risk of Cardiovascular Death or Worsening of Heart Failure in Patients with Mildly Reduced or Preserved Ejection Fraction in DELIVER Phase III Trial | DAIC
AstraZeneca receives China's NMPA approval for Forxiga
EC approves AstraZeneca's Forxiga to treat type-1 diabetes